skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Faricimab for Treatment-Resistant Diabetic Macular Edema

Clinical ophthalmology (Auckland, N.Z.), 2022-08, Vol.16, p.2797-2801 [Peer Reviewed Journal]

COPYRIGHT 2022 Dove Medical Press Limited ;2022. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 Rush and Rush. 2022 Rush and Rush. ;ISSN: 1177-5483 ;ISSN: 1177-5467 ;EISSN: 1177-5483 ;DOI: 10.2147/OPTH.S381503 ;PMID: 36042912

Full text available

Citations Cited by
  • Title:
    Faricimab for Treatment-Resistant Diabetic Macular Edema
  • Author: Rush, Ryan B ; Rush, Sloan W
  • Subjects: Analysis ; Care and treatment ; Cataracts ; Diabetes ; diabetic macular edema ; Diabetic retinopathy ; Dropsy ; Edema ; faricimab ; Medical research ; Medicine, Experimental ; Original Research ; Patients ; recalcitrance ; Tomography ; treatment-resistant
  • Is Part Of: Clinical ophthalmology (Auckland, N.Z.), 2022-08, Vol.16, p.2797-2801
  • Description: Purpose: To assess the short-term outcomes in treatment-resistant diabetic macular edema (DME) patients changed from intravitreal aflibercept (IVA) to intravitreal faricimab (IVF). Methods: A retrospective review was undertaken on DME subjects receiving IVA therapy at a single private practice. Patients were separated into study and control cohorts. Both study and control patients had received more than or equal to six IVA injections during the preceding 12 months, more than or equal to four IVA injections during the preceding 6 months, had a central macular thickness (CMT) on optical coherence tomography (OCT) of [greater than or equal to]300 [micro]m, and had retinal fluid on OCT before cohort assignment. Study patients were switched to IVF and underwent three injections within 4 months, whereas control patients stayed on IVA during the same period and received three injections within 4 months. Results: There were 51 patients analyzed. There were 37.5% (9/24) in the study group and 3.7% (1/27) in the control group who achieved a CMT of less than 300 gm without retinal fluid on OCT at the end of the 4-month study (p=0.001). There were 41.7% (10/24) in the study group and 11.1% (3/27) in the control group who had gained two or more lines of visual acuity at the end of the 4-month study (p=0.01). Conclusion: For a significant minority, IVF can improve the short-term visual and anatomic outcomes in treatment-resistant DME patients formerly managed with IVA. Longer follow-up is needed to determine if such improvements can be preserved. Keywords: faricimab, treatment-resistant, diabetic macular edema, recalcitrance
  • Publisher: Auckland: Dove Medical Press Limited
  • Language: English
  • Identifier: ISSN: 1177-5483
    ISSN: 1177-5467
    EISSN: 1177-5483
    DOI: 10.2147/OPTH.S381503
    PMID: 36042912
  • Source: GFMER Free Medical Journals
    PubMed Central
    ProQuest Central
    DOAJ Directory of Open Access Journals
    Dove Press Free
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait